Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression
Creators: name: Krell, Jonathan
name: Shaw, Danielle
name: McGrane, John
name: Hartkopf, Andreas
name: Herrero, Ana
name: Yeoh, Cheng
name: Masvidal, Maria
name: Raspagliesi, Francesco
name: York, Whitney
name: Schilder, Jeanne M
name: Mascialino, Barbara
name: McDermott, Eleanor
name: Kalilani, Linda
name: Hanker, Lars
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Biotechnology
Mathematical Sciences not elsewhere classified
Developmental Biology
Cancer
Science Policy
Mental Health
Virology

description: <b>Aim:</b> The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer. <b>Patients &amp; methods:</b> Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known <i>BRCA mutation</i>, interval debulking surgery or no surgery, or visible residual disease. <b>Results:</b> Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS. <b>Conclusion:</b> Risk profiles should be carefully considered when planning clinical care. <b>Does the number of risk factors a person with advanced ovarian cancer have affect the likely success of their cancer treatment?</b> Studies have found that individual factors, such as disease stage, and whether any cancer cells remain after surgery are linked to earlier disease worsening and/or shorter survival after treatment in people with advanced ovarian cancer. These are known as ‘risk factors’. However, few studies have looked at whether this link is stronger if a person has several of these risk factors. In this study, we looked at whether outcomes after treatment worsen as the number of risk factors increases. We found that patients with more high-risk factors saw a worsening of their cancer much sooner than those with a fewer number of risk factors. Also, patients with multiple risk factors did not live as long as patients with fewer risk factors. When selecting therapies, healthcare providers should consider the impact of patient risk factors on how effectively that treatment will treat their cancer. The number of high-risk factors may also make an important difference in clinical trials and, therefore, should be considered when comparing results from different clinical trials. This study sought to highlight the cumulative effect of risk factors on disease progression and patient outcomes on patients with ovarian cancer. Most of the patients in the study had more than one high-risk factor, with the majority of patients having two to three. Increasing number of risk-factors correlated with shorter progression-free survival. Patients with greater number of high-risk factors also had worse overall survival. Improving testing and recording of patient <i>BRCA</i> status can help predict patient risk category. The risk profile of patients with ovarian cancer can be an influential factor in patient outcome and disease prognosis and should be considered when making healthcare decisions.